Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge
Authors:
Open Access
- 8 July 2024
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 27 (10) , 1338-1347
Abstract
No abstract availableKeywords
Funding Information
- Department of Health and Social Care
- National Institute for Health Research (NIHR302342)
This publication has 28 references indexed in Scilit:
- Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular DiseaseDiabetes Therapy, 2019
- The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount HoodPharmacoEconomics, 2019
- A Model‐Based Meta‐Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic DosesClinical Pharmacology & Therapeutics, 2018
- Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes MellitusDiabetes Therapy, 2017
- Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)PharmacoEconomics, 2016
- Exploring Structural Uncertainty in Model-Based Economic EvaluationsPharmacoEconomics, 2015
- Review of Utility Values for Economic Modeling in Type 2 DiabetesValue in Health, 2014
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Diabetologia, 2013
- Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6Value in Health, 2012
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002